Haemonetics Corporation $HAE Shares Sold by Isthmus Partners LLC

Isthmus Partners LLC lowered its stake in Haemonetics Corporation (NYSE:HAE) by 10.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 59,256 shares of the medical instruments supplier’s stock after selling 6,695 shares during the period. Isthmus Partners LLC’s holdings in Haemonetics were worth $6,240,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of HAE. Nierenberg Investment Management Company LLC purchased a new stake in shares of Haemonetics in the 2nd quarter worth approximately $1,971,000. Rice Hall James & Associates LLC bought a new position in Haemonetics in the second quarter worth about $3,828,000. Renaissance Technologies LLC bought a new position in Haemonetics in the first quarter worth about $2,435,000. Quantinno Capital Management LP lifted its position in shares of Haemonetics by 438.0% during the first quarter. Quantinno Capital Management LP now owns 30,708 shares of the medical instruments supplier’s stock valued at $1,731,000 after buying an additional 25,000 shares during the last quarter. Finally, Aurora Investment Counsel purchased a new stake in shares of Haemonetics during the second quarter valued at about $1,913,000. Institutional investors own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on HAE. Robert W. Baird boosted their price objective on shares of Haemonetics from $96.00 to $119.00 and gave the stock an “outperform” rating in a research note on Friday, August 21st. Barrington Research raised their target price on shares of Haemonetics from $118.00 to $140.00 and gave the company an “outperform” rating in a research note on Friday, October 9th. Citigroup lifted their price target on shares of Haemonetics from $79.00 to $92.00 and gave the stock a “neutral” rating in a report on Friday, August 7th. BTIG Research lifted their price target on shares of Haemonetics from $110.00 to $130.00 and gave the stock a “buy” rating in a report on Thursday, October 8th. Finally, Wall Street Zen upgraded Haemonetics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $110.00.

Haemonetics Trading Down 0.7%

Shares of Haemonetics stock opened at $116.32 on Friday. The company has a current ratio of 3.08, a quick ratio of 1.91 and a debt-to-equity ratio of 1.40. Haemonetics Corporation has a 12-month low of $48.98 and a 12-month high of $123.77. The firm has a market capitalization of $5.29 billion, a price-to-earnings ratio of 23.38, a PEG ratio of 2.34 and a beta of 0.61. The firm’s 50 day simple moving average is $107.81 and its two-hundred day simple moving average is $83.55.

Haemonetics (NYSE:HAE) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.08 by $0.06. Haemonetics had a net margin of 7.12% and a return on equity of 27.55%. The business had revenue of $339.38 million during the quarter, compared to analysts’ expectations of $327.86 million. During the same quarter last year, the company posted $1.10 earnings per share. The business’s quarterly revenue was up 5.5% on a year-over-year basis. Analysts predict that Haemonetics Corporation will post 5.29 EPS for the current year.

Haemonetics Company Profile

Haemonetics Corporation (NYSE: HAE) is a healthcare technology company that develops and supplies products and services for blood and plasma collection, processing, and management. Its solutions are used by blood and plasma collection organizations, hospitals, and other healthcare providers to support the efficient handling of blood components and improve patient care.

The company’s offerings include automated plasma and blood-component collection systems, disposable collection sets, blood-processing equipment, and software designed to manage collection and transfusion-related operations.